Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood advances Wieduwilt, M. J., Metheny, L., Zhang, M., Wang, H., Estrada-Merly, N., Marks, D. I., Al-Homsi, A. S., Muffly, L., Chao, N. J., Rizzieri, D., Gale, R. P., Gadalla, S. M., Cairo, M. S., Mussetti, A., Gore, S. D., Bhatt, V. R., Patel, S. S., Michelis, F. V., Inamoto, Y., Badawy, S. M., Copelan, E., Palmisiano, N., Kharfan-Dabaja, M. A., Lazarus, H. M., Ganguly, S., Bredeson, C. N., Diaz Perez, M. A., Cassaday, R., Savani, B. N., Ballen, K. K., Martino, R., Wirk, B., Bacher, U., Aljurf, M., Bashey, A., Murthy, H. S., Yared, J. A., Aldoss, I., Farhadfar, N., Liu, H., Abdel-Azim, H., Waller, E. K., Solh, M., Seftel, M., van der Poel, M. W., Grunwald, M. R., Liesveld, J. L., Kamble, R. T., McGuirk, J. P., Munker, R., Cahn, J., Lee, J. W., Freytes, C. O., Krem, M., Winestone, L. E., Gergis, U., Nathan, S., Olsson, R. F., Verdonck, L. F., Sharma, A., Ringden, O., Friend, B. D., Cerny, J., Choe, H. K., Chhabra, S., Nishihori, T., Seo, S., George, B., Baxter-Lowe, L. A., Hildebrandt, G. C., de Lima, M., Litzow, M. R., Kebriaei, P., Hourigan, C. S., Abid, M. B., Weisdorf, D. J., Saber, W. 2021

Abstract

The role of haploidentical hematopoietic cell transplantation (HCT) using post-transplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariate analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) between haploidentical HCT using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD) , 7/8 HLA-matched UD, or umbilical cord blood (UCB) HCT. Comparing haploidentical to MSD HCT, OS, leukemia-free survival (LFS), non-relapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher with MSD HCT. Compared to MUD HCT, OS, LFS, and relapse were not different but MUD HCT had increased NRM (HR 1.42, P=0.02), grade 3-4 aGVHD (HR 1.59, P=0.005), and cGVHD. Compared to 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR 1.38, P=0.01) and increased NRM (HR 2.13, P=<0.001), grade 3-4 aGVHD (HR 1.86, P=0.003), and cGVHD (HR 1.72, P=<0.001). Compared to UCB HCT, late OS , late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (=18 months, HR 1.93, P<0.001), worse early LFS (HR 1.40, P=0.007) and increased incidences of NRM (HR 2.08, P<0.001) and grade 3-4 aGVHD (HR 1.97, P<0.001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared to traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in CR.

View details for DOI 10.1182/bloodadvances.2021004916

View details for PubMedID 34547770